Islam Ghazi

Assistant Professor

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Islam Ghazi is an Assistant Professor at the Philadelphia College of Pharmacy in the United States. His research focuses on clinical outcomes related to infectious diseases, particularly in critically ill patients and those undergoing renal replacement therapy. Recent articles co-authored by Dr. Ghazi explore topics such as the management of Pseudomonal infections, mortality predictors in G6PD-deficient patients, and antimicrobial stewardship interventions for Acinetobacter baumannii infections.

Articles (12)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (1)

Laura Pontiggia

Professor and Director of Academic Programs

Thomas Jefferson University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Islam Ghazi

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy

Clinical Outcomes of Trimethoprim/Sulfamethoxazole in Critically Ill Patients with Stenotrophomonas maltophilia Bacteremia and Pneumonia Utilizing Renal Replacement Therapies

Infections in Glucose-6-Phosphate Dehydrogenase G6PD-Deficient Patients; Predictors for Infection-Related Mortalities and Treatment Outcomes

Urinary tract infections in hemodialysis patients—The controversy of antimicrobial drug urine concentrations

Acinetobacter baumannii Infection-Related Mortality in Hospitalized Patients: Risk Factors and Potential Targets for Clinical and Antimicrobial Stewardship Interventions

Is Cefoxitin a Carbapenem Sparing Agent in the Management of Urinary Tract Infections Caused by ESBL Producing Enterobacterales?

Infections in G6PD-Deficient Hospitalized Patients—Prevalence, Risk Factors, and Related Mortality

Risk Factors for Recurrence of Clostridioides difficile in Hospitalized Patients

Acinetobacter baumannii Infections in Hospitalized Patients, Treatment Outcomes

Optimal vancomycin dose in the treatment of Clostridium difficile infection, antimicrobial stewardship initiative

Cytokine storm is the cryptic killer behind coronavirus disease-2019 infections, review of the current evidence to identify therapeutic options

Optimal vancomycin dose in the treatment of Clostridium difficile infection, antimicrobial stewardship initiative

Collaborators (1)

Laura Pontiggia

Make your next move.